JP2018513123A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513123A5 JP2018513123A5 JP2017547968A JP2017547968A JP2018513123A5 JP 2018513123 A5 JP2018513123 A5 JP 2018513123A5 JP 2017547968 A JP2017547968 A JP 2017547968A JP 2017547968 A JP2017547968 A JP 2017547968A JP 2018513123 A5 JP2018513123 A5 JP 2018513123A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- agent
- pharmaceutical composition
- group
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562132465P | 2015-03-12 | 2015-03-12 | |
| US62/132,465 | 2015-03-12 | ||
| US201662280081P | 2016-01-18 | 2016-01-18 | |
| US62/280,081 | 2016-01-18 | ||
| PCT/US2016/021983 WO2016145298A1 (en) | 2015-03-12 | 2016-03-11 | METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018513123A JP2018513123A (ja) | 2018-05-24 |
| JP2018513123A5 true JP2018513123A5 (https=) | 2019-04-18 |
Family
ID=56879765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547968A Pending JP2018513123A (ja) | 2015-03-12 | 2016-03-11 | Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10959984B2 (https=) |
| EP (1) | EP3268087A4 (https=) |
| JP (1) | JP2018513123A (https=) |
| CN (1) | CN107614062A (https=) |
| HK (1) | HK1249469A1 (https=) |
| WO (1) | WO2016145298A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107614062A (zh) | 2015-03-12 | 2018-01-19 | 加利福尼亚大学董事会 | 用RORγ抑制剂治疗癌症的方法 |
| EP3532062B1 (en) * | 2016-10-27 | 2022-07-20 | Escalier Biosciences, BV | Ror-gamma modulators |
| WO2019023651A2 (en) | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR |
| US20220054496A1 (en) * | 2018-09-13 | 2022-02-24 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncologicas Carlos III (F.S. | Modulation of trf1 for brain cancer treatment |
| WO2020061024A1 (en) * | 2018-09-18 | 2020-03-26 | Yale University | Dermatologic topical applications of ror gamma and ror gamma-t inhibitors for the prevention of skin cancer development |
| WO2020065682A1 (en) * | 2018-09-29 | 2020-04-02 | Translational Health Science And Technology Institute | Ror antagonists, their use and method of treatment comprising the said modulators |
| RU2679625C1 (ru) * | 2018-11-08 | 2019-02-12 | Ильясов Шамиль Сионович | ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-6-ОКСА-7β-МЕТИЛ-D-ГОМО-8α-ЭСТРА-1,3,5(10)-ТРИЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ВКЛЮЧАЯ ТРИЖДЫ-НЕГАТИВНУЮ ФОРМУ, И СПОСОБ ЕГО ПОЛУЧЕНИЯ |
| JP2022520859A (ja) * | 2019-02-20 | 2022-04-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | レチノイン酸受容体関連オーファン受容体γ（ＲＯＲγ）依存性がんのための治療 |
| CN109879784B (zh) * | 2019-03-18 | 2021-06-29 | 中国科学院广州生物医药与健康研究院 | 一种联苯胺类化合物及其应用 |
| EP3946349B1 (en) | 2019-04-03 | 2026-02-25 | University of Florida Research Foundation, Incorporated | Sr-1903 for the treatment of inflammatory, innate immune response or autoimmune disorders |
| WO2021011493A1 (en) * | 2019-07-12 | 2021-01-21 | Duke University | 3' utr crispr-dcas 13 engineering system and methods of using same |
| CN113912563B (zh) * | 2020-07-10 | 2025-05-27 | 中国科学院广州生物医药与健康研究院 | 一种苯并五元氮杂环化合物及其应用 |
| WO2022067185A1 (en) * | 2020-09-27 | 2022-03-31 | Veru Inc. | Methods of treating prostate cancer with minimal side effects |
| WO2022122740A1 (en) * | 2020-12-07 | 2022-06-16 | Diaccurate | Ror-gamma inhibitors for the treatment of ror-gamma-dependent cancer |
| WO2023281097A1 (en) | 2021-07-09 | 2023-01-12 | Immunic Ag | Methods for treating cancer |
| WO2023155846A1 (zh) * | 2022-02-18 | 2023-08-24 | 上海醇健医药技术有限公司 | 17-吡啶基-10α-甲基-甾体衍生物及中间体化合物、其制备方法、其用途、以及其药物组合物 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| DE69311538D1 (de) | 1992-03-12 | 1997-07-17 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5962318A (en) | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| CA2572334A1 (en) | 2004-07-01 | 2006-01-19 | New York University | Compositions and methods for modulation of ror.gamma.t |
| CA2643337C (en) | 2006-03-01 | 2016-01-12 | Janssen Pharmaceutica N.V. | Cancer treatment combining lymphodepleting agent with ctls and cytokines |
| WO2011115892A1 (en) * | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| US9629910B2 (en) * | 2011-03-22 | 2017-04-25 | The Brigham And Women's Hospital, Inc. | Use of Th9 cells and IL-9 for the treatment of melanoma |
| WO2012158784A2 (en) * | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
| WO2013018695A1 (ja) * | 2011-07-29 | 2013-02-07 | 武田薬品工業株式会社 | 複素環化合物 |
| EP2736330A4 (en) | 2011-07-29 | 2015-05-27 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| AU2013254657B2 (en) | 2012-04-27 | 2015-12-24 | Glaxo Group Limited | Novel compounds |
| AR091654A1 (es) | 2012-07-02 | 2015-02-18 | Biogen Idec Inc | COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g |
| US10960057B2 (en) | 2012-07-05 | 2021-03-30 | Nutramax Laboratories, Inc. | Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder |
| WO2014026330A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| WO2014026328A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof |
| WO2014026329A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| EP2929350A4 (en) * | 2012-12-04 | 2016-11-16 | Caris Mpi Inc | MOLECULAR PROFILING OF CANCER |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| WO2014179564A1 (en) | 2013-05-01 | 2014-11-06 | Vitae Pharmaceuticals, Inc. | Thiazalopyrrolidine inhibitors of ror-gamma |
| WO2015008234A1 (en) * | 2013-07-17 | 2015-01-22 | Glenmark Pharmaceuticals S.A. | Bicyclic heterocyclic compounds as ror gamma modulators |
| CN105531274A (zh) | 2013-09-11 | 2016-04-27 | 豪夫迈·罗氏有限公司 | 作为RORc调节剂的酮-咪唑并吡啶衍生物 |
| CN105636941A (zh) | 2013-10-25 | 2016-06-01 | 葛兰素史密斯克莱有限责任公司 | 新的化合物 |
| WO2015082533A1 (en) | 2013-12-05 | 2015-06-11 | Lead Pharma Cel Models Ip B.V. | Ror gamma (rory) modulators |
| WO2015083130A1 (en) | 2013-12-06 | 2015-06-11 | Aurigene Discovery Technologies Limited | Fused pyridine and pyrimidine derivatives as ror gamma modulators |
| CN104530014B (zh) | 2013-12-25 | 2018-03-20 | 中国科学院广州生物医药与健康研究院 | 2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用 |
| WO2015101928A1 (en) | 2013-12-31 | 2015-07-09 | Aurigene Discovery Technologies Limited | Fused thiophene and thiazole derivatives as ror gamma modulators |
| AU2015210833B2 (en) | 2014-02-03 | 2019-01-03 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| CN105272904B (zh) | 2014-07-18 | 2019-04-09 | 中国科学院广州生物医药与健康研究院 | N-苯基酰胺类化合物及其应用 |
| CN107614062A (zh) | 2015-03-12 | 2018-01-19 | 加利福尼亚大学董事会 | 用RORγ抑制剂治疗癌症的方法 |
| WO2017127442A1 (en) | 2016-01-18 | 2017-07-27 | The Regents Of The University Of California | Methods for treating cancer with rorgamma inhibitors |
-
2016
- 2016-03-11 CN CN201680027763.2A patent/CN107614062A/zh active Pending
- 2016-03-11 HK HK18109103.5A patent/HK1249469A1/zh unknown
- 2016-03-11 WO PCT/US2016/021983 patent/WO2016145298A1/en not_active Ceased
- 2016-03-11 EP EP16762587.0A patent/EP3268087A4/en not_active Withdrawn
- 2016-03-11 JP JP2017547968A patent/JP2018513123A/ja active Pending
-
2017
- 2017-09-11 US US15/701,122 patent/US10959984B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513123A5 (https=) | ||
| Mackey et al. | Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial | |
| Folkman | Role of angiogenesis in tumor growth and metastasis | |
| Bahl et al. | Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents | |
| Zurita et al. | Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial | |
| JP2016530280A5 (https=) | ||
| JP2018508516A5 (https=) | ||
| JP2016540738A5 (https=) | ||
| JP2006503919A5 (https=) | ||
| JP2016536352A5 (https=) | ||
| JP2020523354A5 (https=) | ||
| JP2019533651A5 (https=) | ||
| Wang et al. | Molecular treatment of different breast cancers | |
| Ghobrial et al. | Phase Ib study of the novel anti-CXCR4 antibody ulocuplumab (BMS-936564) in combination with lenalidomide plus low-dose dexamethasone, or with bortezomib plus dexamethasone in subjects with relapsed or refractory multiple myeloma | |
| BR112019022308A2 (pt) | Método para o tratamento do câncer usando um inibidor bcl-2 junto com um radioimunoterapêutico emissor alfa | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| Albright et al. | Efficacy of cyclin-dependent kinase 4/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: a case series | |
| Sonpavde et al. | Hormone refractory prostate cancer: management and advances | |
| JP2022543679A5 (https=) | ||
| Ghashghaei et al. | Combining prostate cancer radiotherapy with therapies targeting the androgen receptor axis | |
| WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
| Quintela et al. | Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor | |
| Diamond et al. | The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer | |
| Petrylak et al. | EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC) | |
| Hui | Chemotherapy, Hormonal Therapy, Targeted Agents, and Immunotherapy |